Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY

View Full Paper
Ask AI
Bookmark
Share

Authors

AFAna Rita Da FonsecaDCDennis CarneyDSDon A. Stevens

Discussion

Loading...

Member takes

Overview

Exploratory analysis shows genetic factors affect progression-free survival in chronic lymphocytic leukemia, suggesting targeted treatments may improve outcomes.

Key Points

  • Progression-free survival improved with venetoclax versus chemoimmunotherapy in chronic lymphocytic leukemia patients.
  • Analysis included 867 patients with genetic factors assessed through next-generation sequencing.
  • Subgroup analyses highlighted associations of specific mutations with clinical outcomes and treatment responses.
  • Indicates the potential for tailored therapies based on genetic factors in chronic lymphocytic leukemia management.

Cite This Study

Fonseca et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e21chttps://doi.org/10.1182/blood-2025-3898
View Full Paper
Ask AI
Bookmark
Share